There is a huge unmet need to understand and treat pathological cognitive impairment. The development of disease modifying cognitive enhancers is hindered by the lack of correct pathomechanism and suitable animal models. Most animal models to study cognition and pathology do not fulfil either the predictive validity, face validity or construct validity criteria, and also outcome measures greatly differ from those of human trials. Fortunately, some pharmacological agents such as scopolamine evoke similar effects on cognition and cerebral circulation in rodents and humans and functional MRI enables us to compare cognitive agents directly in different species. In this paper we report the validation of a scopolamine based rodent pharmacological MRI provocation model. The effects of deemed procognitive agents (donepezil, vinpocetine, piracetam, alpha 7 selective cholinergic compounds EVP-6124, PNU-120596) were compared on the blood-oxygen-level dependent responses and also linked to rodent cognitive models. These drugs revealed significant effect on scopolamine induced blood-oxygen-level dependent change except for piracetam. In the water labyrinth test only PNU-120596 did not show a significant effect. This provocational model is suitable for testing procognitive compounds. These functional MR imaging experiments can be paralleled with human studies, which may help reduce the number of false cognitive clinical trials.
AndersonIMClarkL. (2002) 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport13: 1547–1551.
2.
ArmstrongRA (2011) The pathogenesis of Alzheimer’s disease: A reevaluation of the ‘amyloid cascade hypothesis’. Int J Alzheimers Dis2011: 630865.
3.
BalstersJHO’ConnellRG. (2011) Donepezil impairs memory in healthy older subjects: Behavioural, EEG and simultaneous EEG/fMRI biomarkers. PLoS One6: e24126.
4.
BeattyWWButtersNJanowskyDS (1986) Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol45: 196–211.
5.
BraakHBraakE (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol82: 239–259.
6.
BroydSJDemanueleC. (2009) Default-mode brain dysfunction in mental disorders: A systematic review. Neurosci Biobehav Rev33: 279–296.
7.
CaineEDWeingartnerH. (1981) Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology (Berl)74: 74–80.
8.
CaneseRAdrianiW. (2009) Peculiar response to methylphenidate in adolescent compared to adult rats: A phMRI study. Psychopharmacology (Berl)203: 143–153.
9.
ChangCShyuBC (2001) A fMRI study of brain activations during non-noxious and noxious electrical stimulation of the sciatic nerve of rats. Brain Res897: 71–81.
10.
ChenYCGalpernWR. (1997) Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data. Magn Reson Med38: 389–398.
11.
ChinCLUpadhyayJ. (2011) Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: Metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther336: 709–715.
12.
DeakinJFLeesJ. (2008) Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry65: 154–164.
13.
DeNobleVJRepettiSJ. (1986) Vinpocetine: Nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav24: 1123–1128.
14.
DottiCGDe StrooperB (2009) Alzheimer’s dementia by circulation disorders: When trees hide the forest. Nat Cell Biol11: 114–116.
15.
DrachmanDA (2006) Aging of the brain, entropy, and Alzheimer disease. Neurology67: 1340–1352.
16.
DrachmanDA (2014) The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer’s disease. Alzheimers Dement10: 372–380.
17.
DrachmanDALeavittJ (1974) Human memory and the cholinergic system. A relationship to aging?Arch Neurol30: 113–121.
18.
EbertUKirchW (1998) Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest28(11): 944–949.
19.
FerrisCFSmerkersB. (2011) Functional magnetic resonance imaging in awake animals. Rev Neurosci22: 665–674.
20.
FjellAMWalhovdKB (2012) Neuroimaging results impose new views on Alzheimer’s disease – the role of amyloid revised. Mol Neurobiol45: 153–172.
21.
FlickerCSerbyMFerrisSH (1990) Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology (Berl)100: 243–250.
22.
GhoneimMMMewaldtSP (1975) Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacologia44: 257–262.
23.
GouliaevAHSenningA (1994) Piracetam and other structurally related nootropics. Brain Res Brain Res Rev19: 180–222.
24.
GozziALargeCH. (2008) Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology33: 1690–1703.
25.
HacklerEAByunNE. (2010) Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience168: 209–218.
26.
HeidbrederCAGroenewegenHJ (2003) The medial prefrontal cortex in the rat: Evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehav Rev27: 555–579.
KlinkenbergIBloklandA (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev34: 1307–1350.
29.
KlinkenbergISambethABloklandA (2011) Acetylcholine and attention. Behav Brain Res221: 430–442.
30.
KocsisPGajáriD. (2013) Effect of tolperisone on the resting brain and on evoked responses, an phMRI BOLD study. Brain Res Bull99: 34–40.
31.
KocsisPGyertyánI. (2014) Vascular action as the primary mechanism of cognitive effects of cholinergic, CNS-acting drugs, a rat phMRI BOLD study. J Cereb Blood Flow Metab34: 995–1000.
32.
LaszyJLaszlovszkyIGyertyánI (2005) Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl)179: 567–575.
33.
LenzRABakerJD. (2012) The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology (Berl)220: 97–107.
34.
LeslieRAJamesMF (2000) Pharmacological magnetic resonance imaging: A new application for functional MRI. Trends Pharmacol Sci21: 314–318.
35.
McLeanSLIdrisNF. (2012) PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol26: 1265–1270.
36.
MarotaJJMandevilleJB. (2000) Cocaine activation discriminates dopaminergic projections by temporal response: An fMRI study in Rat. Neuroimage11: 13–23.
37.
MolchanSEMartinezRA. (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev17: 215–226.
38.
MorrisRGKopelmanMD (1986) The memory deficits in Alzheimer-type dementia: A review. Q J Exp Psychol A38: 575–602.
39.
OrtnerMKurzA. (2014) Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer’s Disease. Biol Psychiatry. DOI: 10.1016/j.biopsych.2014.01.019
40.
ParóczaiMKissBKárpátiE (1998) Effect of RGH-2716 on learning and memory deficits of young and aged rats in water-labyrinth. Brain Res Bull45: 475–488.
41.
PimplikarSW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int J Biochem Cell Biol41: 1261–1268.
PrickaertsJvan GoethemNP. (2012) EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology62: 1099–1110.
44.
ReeseTBjelkeB. (2000) Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed13: 43–49.
45.
ReitzC (2012) Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis2012: 369808.
46.
SarterMParikhVHoweWM (2009) nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol78: 658–667.
47.
SchwarzAJDanckaertA. (2006) A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. Neuroimage32: 538–550.
48.
SekarSVerhoyeM. (2011) Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging. Psychopharmacology (Berl)213: 521–531.
49.
SnyderPJBednarMM. (2005) Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement1: 126–135.
50.
StarkJADaviesKE. (2006) Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Neuroimage31: 1228–1237.
51.
StarkJAMcKieS. (2008) 5-HT(2C) antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur J Neurosci27: 457–465.
52.
SteinEAPankiewiczJ. (1998) Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry155: 1009–1015.
SunderlandTTariotPN. (1987) Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose- response study. Arch Gen Psychiatry44: 418–426.
55.
WallaceTLBertrandD (2013) Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol85: 1713–1720.
56.
WangZDasSR. (2013) Arterial spin labeled MRI in prodromal Alzheimer’s disease: A multi-site study. Neuroimage Clin2: 630–636.
57.
WesnesKRevellA (1984) The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology (Berl)84: 5–11.
58.
WesnesKWarburtonDM (1983) Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology9: 154–157.
59.
WesnesKWarburtonDM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl)82: 147–150.
60.
WeversA (2011) Localisation of pre- and postsynaptic cholinergic markers in the human brain. Behav Brain Res221: 341–355.
61.
ZhouXQiXL. (2011) Cholinergic modulation of working memory activity in primate prefrontal cortex. J Neurophysiol106: 2180–2188.
